Heat treatment of thioredoxin fusions increases the purity of α‐helical transmembrane protein constructs by Schenkel, Mathias et al.
METHOD S AND A P P L I C A T I ON S
Heat treatment of thioredoxin fusions increases the purity
of α-helical transmembrane protein constructs
Mathias Schenkel1 | Antoine Treff1 | Charles M. Deber2 | Georg Krainer1,3 |
Michael Schlierf1
1B CUBE – Center for Molecular
Bioengineering, TU Dresden, Dresden,
Germany
2Division of Molecular Medicine,
Research Institute, Hospital for Sick
Children, Toronto, Ontario, Canada
3Centre for Misfolding Diseases, Yusuf
Hamied Department of Chemistry,
University of Cambridge, Cambridge, UK
Correspondence
Michael Schlierf and Georg Krainer, B
CUBE – Center for Molecular
Bioengineering, TU Dresden, Tatzberg
41, 01307 Dresden, Germany.
Email: michael.schlierf@tu-dresden.de
(M. S.) and gk422@cam.ac.uk (G. K.)
Funding information
Boehringer Ingelheim Stiftung; Canadian
Institutes of Health Research, Grant/
Award Number: 376666; Cystic Fibrosis
Canada; European Social Fund; H2020
Marie Skłodowska-Curie Actions, Grant/
Award Number: 841466; Herchel Smith
Funds; Mukoviszidose Institut gGmbH;
Wolfson College Junior Research
Fellowship
Abstract
Membrane proteins play key roles in cellular signaling and transport, represent
the majority of drug targets, and are implicated in many diseases. Their relevance
renders them important subjects for structural, biophysical, and functional investi-
gations. However, obtaining membrane proteins in high purities is often challeng-
ing with conventional purification steps alone. To address this issue, we present
here an approach to increase the purity of α-helical transmembrane proteins. Our
approach exploits the Thioredoxin (Trx) tag system, which is able to confer some
of its favorable properties, such as high solubility and thermostability, to its fusion
partners. Using Trx fusions of transmembrane helical hairpin constructs derived
from the human cystic fibrosis transmembrane conductance regulator (CFTR) and
a bacterial ATP synthase, we establish conditions for the successful implementa-
tion of the selective heat treatment procedure to increase sample purity. We fur-
ther examine systematically its efficacy with respect to different incubation times
and temperatures using quantitative gel electrophoresis. We find that minute-
timescale heat treatment of Trx-tagged fusion constructs with temperatures rang-
ing from 50 to 90C increases the purity of the membrane protein samples from
~60 to 98% even after affinity purification. We show that this single-step approach
is even applicable in cases where regular selective heat purification from crude
extracts, as reported for Trx fusions to soluble proteins, fails. Overall, our approach
is easy to integrate into existing purification strategies and provides a facile route
for increasing the purity of membrane protein constructs after purification by stan-
dard chromatography approaches.
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1 | INTRODUCTION
Membrane proteins are important actors in cross-
membrane cell physiology and fulfill a variety of
functions ranging from cellular signaling to energy gener-
ation and transport.1,2 They cover about 20–50% of pro-
karyotic and eukaryotic genomes,2 and constitute more
than 50% of all approved drug targets.3 Many membrane
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proteins are involved in the pathogenesis of several
severe diseases (e.g., cystic fibrosis) due to their mis-
folding from sequence mutations.4 Their abundance and
therapeutic relevance, therefore, render them important
subjects for structural, functional, and biophysical inves-
tigations in proteomics, interactomics, and in vitro drug
screening workflows.5,6
High sample purity is vital for studying membrane
proteins and their respective segmental model constructs,
such as single transmembrane helices and helical hair-
pins that preserve many characteristics of their full-
length counterparts.7,8 In fact, in vitro investigations of
membrane proteins, such as structural studies and single-
molecule experiments, typically demand milligram
amounts of highly pure protein samples. For instance, X-
ray crystallography studies require sample purities of
more than 90–95%.9 To achieve this, the production
of membrane proteins typically involves overexpression
of constructs in heterologous hosts10,11 and purification
by chromatography techniques such as, for example,
immobilized metal affinity chromatography (IMAC).12
Prior to chromatographic separation, the protein of inter-
est is usually extracted from the expression host cell
membrane. This is achieved with adequate solubilization
agents, such as detergents, to keep the hydrophobic pro-
teins in solution as water-soluble protein–detergent com-
plexes in order to prevent aggregation.7,13
To increase the solubility of membrane protein con-
structs, tags are often added to the protein of interest,14
among them thioredoxin (Trx),15,16 a thermostable pro-
tein with a high melting temperature (Tm) of ~85C.
17,18
It was first presented by LaVallie et al.19 as a solubility
fusion tag for cytokines and mammalian growth factors.
Protocols have been established describing the construc-
tion of Trx gene fusions for expression as well as facile
steps for purification of the Trx fusion proteins.20,21 In
addition to its role in increasing protein solubility, Trx-
tagged constructs can be purified by heat treatment due
to their retained thermal stability from whole-cell
lysate.19 In fact, Trx can resist long incubations at high
temperatures (80–90C) without denaturing, a character-
istic that is often preserved in Trx fusions and which
enables heat treatments to be exploited as an effective
purification method for Trx-tagged proteins.19–21
The ability of Trx fusions to withstand heat treatment
provides an opportunity to use this system as a tool for
the purification of membrane proteins. Indeed, we have
used the Trx tag to increase the purity of
transmembrane–Trx fusion proteins in elution fractions
gained after affinity chromatography. A helical hairpin
peptide derived from the third and fourth transmem-
brane helix (TM3/4) of the human cystic fibrosis trans-
membrane conductance regulator (CFTR)22,23 solubilized
in detergent was subjected to heat treatment at 70C for
10 min and subsequent centrifugation to obtain highly
pure samples of Trx–TM3/4 fusion proteins. This exem-
plifies the simplicity and effectiveness of the Trx-based
selective heat treatment procedure for increasing the
purity of helical membrane protein constructs. Yet a sys-
tematic evaluation and demonstration of the approach
has been lacking.
Here we assess the efficiency of the heat treatment
approach for the selective purification of Trx-tagged
transmembrane protein constructs and systematically
examine its efficacy with respect to different incubation
times and temperatures. As model systems, we evaluate
Trx fusions of the CFTR-derived mutant helical hairpin
Q220R TM3/4,24 denoted as Trx–TM3/4Q220R, and the
subunit C transmembrane peptide derived from the ATP
synthase of Ilyobacter tartaricus (I. tartaricus),25 denoted
as Trx–subunit C. We use quantitative sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) to
determine optimal conditions for the heat treatment puri-
fication procedure and evaluate the impact of the heat
treatment on secondary structure by circular dichroism
(CD). We further probe if the fusion proteins can be
selectively purified from whole-cell crude extract, similar
to previous protocols.19–21 We find that heat treatment
increases the purity of affinity-purified Trx transmem-
brane fusion constructs in elution fractions while
retaining their native conformation. In conclusion, we
establish conditions and guiding principles for the purifi-
cation of Trx transmembrane fusion proteins by the heat
treatment procedure. Our approach is easy to integrate
into existing purification strategies and thus provides a
facile route for obtaining purer samples for structural,
biophysical, and biochemical studies on membrane pro-
tein constructs.
2 | RESULTS AND DISCUSSION
To examine the efficiency of selective heat treatment and
determine optimal conditions for the purification proce-
dure, we evaluated the heat stability of purified Trx–
TM3/4Q220R and Trx–subunit C fusion proteins
(Figure 1a) at different temperatures and incubation
times. A schematic of the heat treatment procedure is
shown in Figure 1b and details on construct design for
Trx–TM3/4Q220R and Trx–subunit C can be found in
Figure 2a and Figure 3a, respectively.
We expressed the two fusion proteins in Escherichia
coli BL21 (DE3), harvested and lysed the cells, clarified
the lysate, and purified the His-tagged Trx fusion proteins
by IMAC (see Methods). As both fusion constructs harbor
transmembrane proteins as fusion partners, the buffers
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contained Triton X-100 to aid in solubilization. The elu-
tion fractions were concentrated and heat treated at vary-
ing temperatures and incubation times. In one series of
experiments, we treated the samples at temperatures
between 50 and 90C for a fixed incubation time of
10 min. In another set of experiments, we heat treated
the samples for 1–60 min at 70C. In addition, we probed
if the fusion proteins can be selectively purified from
E. coli crude extract, similar to previous protocols.19–21
Crude purification was done by lysing cells expressing
the two Trx fusion proteins and clarifying the cell lysate
by centrifugation. The soluble fraction was then incu-
bated at 50–90C for 10 min.
For all procedures, we subjected the heat-treated
sample to SDS-PAGE and quantitatively analyzed the
band intensities (see Methods). Specifically, we
assessed purity and recovery of band intensity of the
respective Trx fusion proteins. Purity represents the
fraction of intensity of the band of interest (e.g., Trx–
TM3/4Q220R or Trx–subunit C) over the total intensity
of all bands in one sample (i.e., entire lane). Recovery
denotes the fraction of intensity of the band of interest
in heat-treated samples over the intensity of the band
of interest in the untreated sample (e.g., elution frac-
tion), that is, the amount of protein that remains solu-
ble after heat treatment.
Heat Treatment & Centrifugation4
ΔT
Expression1 Lysis & Centrifugation2 Chromatography3
Trx–TM3/4Q220R Trx–subunit C(a)
(b)
FIGURE 1 Heat treatment of Trx-tagged α-helical transmembrane constructs. (a) Representation of Trx-tagged fusions (yellow, PDB ID:
2TRX)30 of the TM3/4Q220R hairpin derived from human CFTR (red, PDB ID: 5UAK)31 (left panel) and the ATP synthase subunit C of
Ilyobacter tartaricus (green, PDB ID: 1YCE)32 (right panel). Structures were created using UCSF Chimera (version 1.13.1).36 (b) Schematic of
the heat treatment assay. Step 1: Expression. Trx fusion proteins are expressed heterologously in a suitable host (e.g., E. coli). Step 2: Lysis and
centrifugation. Cells containing the fusion construct are lysed, followed by centrifugation to clarify the lysate. Step 3: Chromatography.
Chromatography methods, such as affinity chromatography (e.g., IMAC), serve as an initial purification step to enrich the target protein and
separate it from undesired and contaminating cellular proteins. Step 4: Heat treatment and centrifugation. Incubation at elevated
temperatures and subsequent centrifugation yields high purity of Trx fusion proteins in the supernatant. Trx–TM3/4Q220R is shown as an
example for thermostable Trx fusion constructs. Protein contaminants are displayed in gray
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For Trx–TM3/4Q220R (Figure 2), sample purity in the
untreated elution fraction after IMAC amounted to ~66%.
Incubation at a rather low temperature of 50C already
markedly increased the purity of the fusion protein to
~91% (Figure 2b,c). Raising the temperature further in
the heat treatment increased the purity of the fusion con-
struct, maxing out at 70C with remarkable ~98% purity.
However, incubation at higher temperatures was also
accompanied by a substantial reduction in recovery of
the TM3/4 construct (Figure 2b,c). At 70C, only ~65% of
the initial Trx–TM3/4Q220R band intensity remained. A
further increase of temperature gradually reduced the
recovery of the fusion construct to as low as ~21% at
90C. The loss of Trx–TM3/4Q220R is clearly visible in the
lanes for the temperature range between 70 and 90C
(Figure 2b). Overall, our findings suggests that protein
contaminants can be efficiently removed from elution
fractions by denaturation and precipitation using the heat
treatment protocol over the entire temperature range,
with Trx–TM3/4Q220R still remaining soluble. Nonethe-
less, elevated temperatures above 70C reduce the solu-
bility of Trx–TM3/4Q220R markedly. Altering incubation
times for the heat purification of Trx–TM3/4Q220R at 70C
showed that a purity of ~95% can already be reached after
just 1 min of incubation (Figure 2c,d). Accordingly, lon-
ger incubation periods did not greatly increase the purity
of the elution fraction but did decrease the recovery of
Trx–TM3/4Q220R to ~60% after 60 min of incubation.
For the Trx–subunit C fusion (Figure 3), the
untreated elution fraction showed a purity of ~52% for
the monomeric Trx–subunit C band after IMAC
(Figure 3b,c). Notably, an intense band at a molecular
weight of >250 kDa was present as well (Figure 3b). A
possible explanation for this high molecular weight band
may be native oligomers or aggregates of Trx–subunit C,
which did not migrate deeply into the gel, since subunit c
is more prone to form aggregates when heterologously
expressed.26 These oligomeric rings and aggregates of
subunit c are even resistant to boiling in SDS, especially
in presence of Na+ ions.27,28 However, in comparison to
subunit C without Trx-tag,27,28 Trx-subunit C is largely
present in a monomeric state (Figure 3b), suggesting that
Trx prevents aggregation and aids in retaining subunit c
as a soluble monomer. A strong increase in purity of Trx–
subunit C as well as a loss of the band at >250 kDa
occurred at temperatures above 70C, peaking at 80C
with a purity of ~97% (Figure 3b,c). Thus, heating Trx-

















































































FIGURE 2 Heat treatment of the Trx–TM3/4Q220R fusion construct. (a) Design of the Trx–TM3/4Q220R construct. Trx is N-terminally
fused to the CFTR TM3/4 hairpin mutant via an internal His6-Tag, a cleavage site for thrombin (gray arrow), and an S-Tag. TM3/4
Q220R
bears an additional C-terminal His5-tag. (b) 12% SDS-PA gel with heat treatment series of a concentrated Trx–TM3/4Q220R elution fraction
after IMAC. Lanes show the untreated fraction (UT), heat incubations for 10 min at different temperatures, and different incubation
durations at 70C. Molecular weight marker (M) and expected molecular weight of the Trx–TM3/4Q220R band (~23.5 kDa, black arrow) are
indicated. (c) Purity and recovery of Trx–TM3/4Q220R after heat treatment at different temperatures for 10 min. Values are normalized with
respect to the untreated sample. (d) Purity and recovery of Trx–TM3/4Q220R after heat treatment for different incubation durations at 70C.
Values are normalized with respect to the untreated sample
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Methods) at >70C is an effective approach to remove
any aggregates preceding other studies, as they could, for
example, remain to some extent even after boiling in
SDS-loading buffer (Figure 3b). The heat treatment, how-
ever, was again accompanied by a decrease in recovery
(e.g., to ~41% recovery at 70C). Remarkably, Trx–
subunit C seems to be less heat stable than Trx–
TM3/4Q220R, as the Trx–subunit C band showed only
~10% recovery at 80C and only ~1% recovery at 90C
(Figure 3b,c). When varying incubation times at 70C
(Figure 3b,d), purity of Trx–subunit C could only be
increased by treatment durations longer than 5 min, with
purity of Trx–subunit C plateauing at ~90% and recovery
dropping from ~51% after 5 min of treatment to ~20%
after 60 min of treatment.
In addition, we investigated whether the heat
treatment of the fusion constructs had an impact on their
secondary structure by employing CD spectroscopy
(Figure S1). For this purpose, the buffer of the respective
Trx-tagged construct was exchanged to a buffer with a
composition suitable for CD analysis (see Methods). At
20C, the CD spectra of both fusion proteins, Trx–
TM3/4Q220R and Trx–subunit C, showed a negative band
between 208 and 222 nm, with a distinct peak at
~208 nm, typical for α-helical proteins.29 While Trx is an
α/β protein,30 TM3/4 and subunit C are both α-helical
peptide hairpins,31,32 thus the fusion proteins are
expected to mostly have a signature characteristic of an
α-helical structure. Upon temperature increase from
20 to 90C, the ellipticity of both fusion proteins only
slightly increased, as quantified for ellipticity values at
208 and 222 nm (Figure S1). Especially Trx–TM3/4Q220R
appeared to be resistant to thermal unfolding, while Trx–
subunit C's structure appeared to be more affected at
high temperatures (80–90C), in agreement with our
observation of reduced recovery at elevated temperatures
for Trx–subunit C (Figure 3). Overall, our results from
CD experiments indicate that Trx’ exceptional conforma-
tional stability over a wide temperature range33 is indeed
shared with its transmembrane fusion proteins and sec-
ondary structure is preserved.
We further asked whether the Trx-tagged transmem-
brane constructs can be selectively purified from E. coli
crude extract, to circumvent affinity purification, as pre-
viously shown for soluble proteins such as growth factors
and cytokines.19–21 To this end, we lysed E. coli cells
expressing Trx–TM3/4Q220R and Trx–subunit C and clari-
fied the cell lysate by centrifugation. Samples of the cell
pellet, cell lysate, and soluble fraction of the respective
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ATP synthase subunit CThioredoxin S-Tag 5xHis
FIGURE 3 Heat treatment of the Trx–subunit C fusion construct. (a) Design of the Trx–subunit C construct. Trx is N-terminally fused
to the ATP synthase subunit C of Ilyobacter tartaricus via an internal S-Tag and cleavage sites for thrombin and enterokinase (cleavage
positions are indicated with gray and brown arrows, respectively). Subunit c bears an additional C-terminal His5-tag. (b) 12% SDS-PA gel
with heat treatment series of a concentrated Trx–subunit C elution fraction after IMAC. Lanes show the untreated fraction (UT), heat
incubations for 10 min at different temperatures, and different incubation durations at 70C. Molecular weight marker (M) and expected
molecular weight of the Trx-subunit C band (~25.8 kDa, black arrow) are indicated. (c) Purity and recovery of Trx–subunit C after heat
treatment at different temperatures for 10 min. Values are normalized to the untreated sample. (d) Purity and recovery of Trx–subunit C
after heat treatment for different incubation durations at 70C. Values are normalized with respect to the untreated sample
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soluble fraction was then subjected to heat treatment at
different temperatures ranging from 50 to 90C for
10 min. For Trx–TM3/4Q220R, purity only increased from
~18% of the untreated sample to around ~37–38% at
60 and 70C, while the recovery dropped to ~82
and ~ 62% at 60 and 70C, respectively (Figure S2).
Higher temperatures yielded an even lower recovery, as
low as ~2% at 90C. We reason that this effect is caused
by a co-precipitation of Trx–TM3/4Q220R with heat-labile
proteins that are still present in the soluble fraction, even
to an extent where Trx–TM3/4Q220R is more precipitated
than some contaminants, which could explain the drop
in purity of Trx–TM3/4Q220R at 80C and 90C. Likewise,
a selective purification of Trx–subunit C from the soluble
fraction of an E. coli cell lysate could not be achieved
(Figure S2), as heat treatment with increasing tempera-
tures only reduced the purity and recovery of Trx–
subunit C. We suspect that similar to Trx–TM3/4Q220R,
co-precipitation of Trx–subunit C with other lysate pro-
teins decreases the recovery strongly.
3 | CONCLUSIONS
We have demonstrated here that the purity of Trx-tagged
transmembrane constructs can be considerably
improved, up to ~98%, by heat treatment after initial
purification steps such as affinity chromatography. To
maximize purity and recovery of Trx–TM3/4Q220R from
IMAC elution fractions, heat treatment could either be
performed at lower temperatures for longer incubation
periods (e.g., at 50C for 10 min) or, complementary, at
higher temperatures for shorter durations (e.g., at 70C
for 1 min). To increase purity of Trx–subunit C, optimal
heat treatment conditions were found at 70C for 5 min,
to efficiently remove aggregates and other contaminants,
while retaining a sufficient amount of the fusion protein.
We observed that the Trx-subunit C fusion protein (Trx:
11.8 kDa + subunit C: 8.7 kDa) was less thermostable
than Trx–TM3/4Q220R (Trx: 11.8 kDa + Q220R TM3/4:
5.1 kDa), suggesting that the heat treatment approach
could be limited by the size of the fusion partner. It is
possible that the thermostable properties conferred by
Trx are attenuated when using a bigger interaction part-
ner, though this remains to be explored. We have further
demonstrated that the secondary structure integrity of
the Trx fusion constructs is maintained at these tempera-
tures. While selectively purifying Trx fusion constructs
from whole-cell crude extracts, as demonstrated
previously,19–21 is conceptually straightforward, it may
only be feasible for certain classes of well-soluble pro-
teins. Our results suggest that helical membrane protein
constructs evade such a strategy. Therefore, selective
purification of membrane proteins, as demonstrated
here, can be achieved by heat treatment after purifica-
tion by for example, affinity chromatography. We
expect that our one-step protocol for increasing the
purity of Trx fusion constructs will be beneficial for
many applications where high membrane protein
purity is required, for example, in crystallization
attempts for structural studies9 or in investigations of
membrane proteins by single-molecule techniques.34
We anticipate that the presented purification system
might be also applicable to intrinsically disordered
proteins or unstable non-membrane proteins.
4 | MATERIALS AND METHODS
Trx–TM3/4Q220R was expressed from a pET32a expression
vector (Merck) and the Trx–subunit C fusion construct
was expressed from a pET24a expression vector
(GenScript). Plasmids harboring the fusion constructs
were transformed into E. coli One Shot BL21 Star (DE3)
cells (Life Technologies). Expression was performed
according to our previously described protocol.22 In brief,
starter cultures were grown in Luria–Bertani
(LB) medium, supplemented with 100 μg/ml ampicillin
(for pET32a) or 50 μg/ml kanamycin (for pET24a), at
37C overnight. These cultures were used to inoculate
expression cultures in M9 minimal medium prepared
from M9 minimal salt and containing 1 mM MgSO4,
0.1 mM CaCl2, 0.001% (wt/vol) thiamine, 0.001% (wt/vol)
biotin, 3 g/L glucose and the respective antibiotic concen-
tration as denoted above. Cell cultures were further culti-
vated at 37C and induced at an OD of ~0.6–0.7 with a
final concentration of 1 mM IPTG, followed by protein
expression at 20C overnight with subsequent centrifuga-
tion to harvest the cells. Pellets were washed with PBS
and stored at 80C or immediately used for protein
purification.
Purification was initiated by thawing the pellets on
ice with subsequent resuspension in lysis buffer (20 mM
Tris–HCl, 150 mM NaCl, 0.1% (wt/vol) Triton X-100,
10 mM β-mercaptoethanol, 5 mM imidazole, pH 8.0)
under addition of 0.1 μl/ml Benzonase (Merck). Cells
were lysed with an Emulsiflex high-pressure homoge-
nizer (Avestin) or by sonication using a MS 73 sonication
tip (Bandelin). The lysate was clarified by centrifugation
and the soluble fraction was added to a Ni-NTA resin
(Qiagen) which was previously equilibrated with binding
buffer (20 mM Tris–HCl, 150 mM NaCl, 0.1% (wt/vol)
Triton X-100, 10 mM β-mercaptoethanol, 5 mM imidaz-
ole, pH 8.0). The lysate-resin mixture was incubated
under rotation for 90 min at room temperature and trans-
ferred into gravity flow columns to perform IMAC. The
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resin was washed stepwise with 20 mM Tris–HCl,
300 mM NaCl, 0.1% (wt/vol) Triton X-100, 10 mM
β-mercaptoethanol, pH 8.0, supplemented with 5, 15,
25, and 50 mM imidazole. A final wash with binding
buffer (containing 50 mM imidazole) was performed
and His-tagged Trx fusion proteins were eluted with
elution buffer (20 mM Tris–HCl, 150 mM NaCl, 0.1%
(wt/vol) Triton X-100, 10 mM β-mercaptoethanol,
400 mM imidazole, pH 8.0). Protein expression and
purification was checked by SDS-PAGE. PageRuler
Plus Prestained Protein Ladder (Thermo Fisher) was
used as a molecular weight marker for all SDS-PAGE
analyses. Elution fractions were stored at 80C until
further use.
Subsequently, elution fractions were thawed on ice
and concentrated with a Vivaspin 6 centrifugal con-
centrator (5 kDa molecular weight cut-off (MWCO),
Sartorius) for 3–3.5 hr at 7,000g and 4C; yielding a
3.4-times concentrated elution fraction for Trx–
TM3/4Q220R (6 to 1.75 ml) and a five-times concen-
trated elution fraction for Trx-subunit C (6 to 1.2 ml),
which were stored at 20C if not used immediately.
Afterwards, the concentrated elution fractions were
aliquoted (each 40 μl) and heat-treated for 10 min at
50–90C (10C steps, temperature series) or at 70C for
1, 5, 10, 20, or 60 min (time series). Heat treated sam-
ples were then immediately centrifuged for 10 min at
20,817g, 4C and the supernatants of each series were
analyzed on a 12% SDS-PA gel, after boiling (95C,
10 min), loading equal sample amounts. To assess if
heat treatment of Trx fusion constructs can be per-
formed directly from the soluble fraction of a cell
lysate, both fusion constructs were expressed and puri-
fied again as stated above (according to our previous
protocol)22 until obtaining the soluble fraction of the
cell lysates, taking additional samples from the cell
pellet, lysate and soluble fraction. A heat treatment
series was then performed with aliquots of the soluble
fraction (each 1 ml) for 10 min at 50–90C (10C steps).
Heat treated samples were centrifuged for 10 min at
20,817g and the supernatants were analyzed together
with the pellet, lysate, and the soluble fraction on a
12% SDS-PA gel, after boiling (95C, 10 min), loading
equal sample amounts. Ultimately, all gels were
scanned with a resolution of 600 dpi using a CanoScan
9000F flatbed scanner (Canon) and saved as tagged
image file format (TIF) files. Gel images were analyzed
manually with the gel analyzer function of Fiji
(ImageJ 1.52p).35 Before analysis, gel images were
converted to 8-bit grayscale images and a rolling ball
background subtraction with a pixel size of 400 was
performed to increase contrast.
To perform CD spectroscopy, the buffer of non-
concentrated or concentrated elution fractions of the
fusion constructs was exchanged to CD buffer (20 mM
Tris, 0.3% [wt/vol] SDS, pH 7.0) in several steps by
employing His SpinTrap columns (GE Healthcare) and
dialysis using Slide-A-Lyzer 10 K dialysis cassettes
(10 kDa MWCO, Thermo Fisher). Protein concentration
was estimated by SDS-PAGE by comparing band intensi-
ties to a bovine serum albumin (BSA) standard row with
known concentrations. Dialyzed samples were stored at
20C until CD spectroscopy was performed. CD spectra
were recorded employing a Chirascan-plus spectrometer
(Applied Photophysics) in the far-UV range between a
wavelength of 195–260 nm with a step size of 0.5 nm,
a spectral bandwidth of 1 nm, a scanning speed of 30 nm
per min, and a digital integration time of 1 s. The mea-
surement temperature was raised from 20 to 90C in
10C increments. Samples were analyzed in a 1-mm path
length quartz glass cuvette, blanked against CD buffer
(20 mM Tris, 0.3% [wt/vol] SDS, pH 7.0) and spectra were
scanned five times and averaged.
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